

Daring to Go Beyond

CELLTRION EARNINGS RELEASE

SECOND-QUARTER 2026

2026.07.27

Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external review is completed. The results of the external auditor's review may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.

01

2Q26 Financial Highlights

2Q26 Financial Highlights



Record-high Quarterly Revenue and Profitability Expansion Realized

Driven by Accelerated Momentum of Young Products upon Stable Growth of Advanced Products

[Unit: KRW billion]

	2Q26	1Q26	QoQ	2Q25	YoY
Sales	1,393.7	1,145.0	+21.7%	961.5	+45.0%
Biologics	1,263.9	974.2	+29.7%	882.8	+43.2%
Non-Biologics	129.8	170.8	-24.0%	78.7	+64.9%
Operating Profit	451.8	321.9	+40.4%	242.5	+86.3%
OP Margin	32.4%	28.1%	+4.3%p	25.2%	+7.2%p

Sales Increased +45.0% YoY

- Biologics revenue grew sharply, led by +76% YoY surge in Young Products and solid growth from Advanced Products based on stable market shares
- Most products recorded rapid growth, driven particularly by the five Young Products launched in 2025
- Annual revenue is projected to outperform initial guidance, supported by accelerated market penetration of Young Products



OP Increased +86.3% YoY

- OP surpassed KRW 400 billion for the first time in 2Q, driven by top-line growth of high-margin Young Products which accounted for 65% of total biologics revenue
- Improved mix and fixed-cost leverage boosted profitability (OPM trend: 8.3%(2Q24)→ 25.2%(2Q25) → 32.4%(2Q26))
- Profitability is expected to improve further in 2H26, meeting full-year guidance

Biologics Global Market Sales



- Young Portfolio sales surged +76% YoY, surpassing KRW 800 billion in quarterly revenue as its contribution expanded to 65%
- Advanced Products sales increased +6% YoY, supported by robust Truxima performance in the US
- Growth momentum is set to accelerate in 2H26, driven by regional rollout expansion, putting the full-year target of 70% revenue share comfortably within reach



* Advanced: Remsima, Truxima, Herzuma / Young: RemsimaSC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt
* 2023: Pre-merger Celltrion Healthcare's sales

Biologics Sales (by Product)





- Sales driven by high-margin Young Products (+356.8bn), led by 4.7x YoY surge in 5 newly launched products. Remsima SC expanded in EU & Zymfentra showed two-folds prescription growth YoY, while Yuflyma in EU sustaining #1 M/S and expanding US sale by Low-WAC strategy
- Advanced Product sales up KRW 24.2bn YoY, driven by Truxima; optimized pricing expanded US long-term contracts, increasing both sales and M/S [Truxima US M/S: 4Q25 31% → 1Q26 35% → 2Q26 38%]

High-margin Young Products* ▲ KRW 356.8 bn

Advanced Products* ▲ KRW 24.2 bn


[Unit: KRW billion]



* 5 new products: Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt
* Advanced Products: products launched before 2020 / Young Products: launched between 2020–2024 / 5 new products: Launched in 2025 and thereafter

North America Direct Sales Platform Gains Momentum

- North America direct sales revenue surpassed 200bn in 2Q26, driven by the successful settlement of the system and portfolio expansion (1 in 2023 → 6 in 2Q26)
- Secured a sustainable growth foundation as launched products ramp up and 2H pipeline additions are expected



Accelerating Performance & Securing Growth Engines

1 Successful establishment of direct sales system

- ✓ Expertise gained through initial direct sales products (Vegzelma, Yuflyma, Zymfentra)
- ✓ Fully internalized sales capabilities: PBM contracts, channel management, pricing strategies

2 Accelerating growth backed by Young Portfolio

- ✓ Initial market penetration sped up based on sales capabilities
- ✓ Sales ramp-up of Young Products
 - Steqeyma, Stoboclo&Osenvelt ranked #2 in biosimilar market share
- ✓ Launches scheduled for 2H: Omlyclo(First-mover) and Eydenzelt—revenue growth expected to accelerate

3 Zymfentra's sustained growth

- ✓ Maintaining strong momentum with an average monthly prescription growth rate of +23% since launch
- ✓ Branchburg (US) production slated following validation → Enhances supply stability + tariff risks eliminated

1. North American direct sales exclude indirect sales products(Remsima, Truxima, Herzuma)

*2023: Pre-merger Celltrion Healthcare's sales

- Cash and cash equivalents decreased leading to a slight increase in net debt, while the debt ratio remained stable at 30%, still significantly below the average debt level of large conglomerates in Korea


Statement of Financial Position Summary

[Unit: KRW billion]

Category	End of 2025	2Q26
Total Assets	22,335	23,703
Current Assets	6,205	6,976
- Cashable Assets ¹	1,237	1,199
- Trade Receivables	1,790	2,220
- Inventory Assets	2,804	2,941
Non-current Assets	16,130	16,727
- Intangible Assets	13,778	14,188
Total Liabilities	4,982	5,655
Current Liabilities	4,454	5,114
Non-current Liabilities	529	541
* Borrowings (Long- and Short-term)	3,690	3,826
Shareholder's Equity	17,353	18,048
Issued Capital	239	251
Share Premium	14,190	14,236
Retained Earnings	4,407	3,288
Accumulated other comprehensive income	310	621
Other components of equity	(1,938)	(493)

Net Debt and Debt-Equity Ratio

[Unit: KRW billion]



1. Cashable Assets: cash and cash equivalent, and short-term financial instrument

1. Net debt: borrowings (long & short term) – cashable assets

2. Debt to Equity Ratio: total liabilities /shareholder's equity

3. Average debt ratio of large conglomerates (manufacturing sector) based on the Bank of Korea's "Corporate Management Analysis."




02

Global Commercial Update

Remsima / Inflectra (Infliximab IV)




- Maintaining steady No.1 position with a dominant market share in key markets
- Expanding market leadership and Infliximab franchise prescriptions by leveraging the unique synergy of a comprehensive portfolio across IV(lyophilized & liquid) and SC formulations



* Based on infliximab IV market (Excluding SC)

* Source: IQVIA, Farminform





* Based on infliximab IV market (Excluding SC)

* Source: IQVIA, Symphony Health

Truxima (Rituximab) & Herzuma (Trastuzumab)



- Expanding leadership in core markets across Europe, US, and Japan, to secure solid foundation for growth
 - Truxima: Maintained a stable ~30% M/S in Europe; achieved the #1 position in the US through a rapid share increase driven by expanded long-term supply contracts, securing a foundation for further growth
 - Herzuma: Maintained #1 position in Europe as M/S rebounded to the 30% range; leadership in Japanese market expected to further solidify with all-time high M/S of 78%



* Market share based on prescription volume

* Source : IQVIA, Farminform, Symphony Health


* Market share based on prescription volume

* Source: IQVIA, Farminform


Remsima SC & Zymfentra (Infliximab SC)



- Remsima SC hits a record 32% share in EU5, breaking records every quarter; prescription expanding steadily across all of Europe
- Zymfentra established its position as a novel drug within the US autoimmune disease market, demonstrating steady quarterly prescription growth since its launch



1. Based on EU5 infliximab market
* Data based on SC dose-adjusted prescription volume * Source: IQVIA, Farminform




2. Symphony Health data used as IQVIA data was unavailable as of 2Q earnings release date
* Soucce: Symphony Health

Yuflyma (Adalimumab) & Vegzelma (Bevacizumab)




- In Europe, Yuflyma and Vegzelma are expanding market share, solidifying #1 position based on portfolio synergy and direct sales capabilities
- In the US, Yuflyma share gain is expanding via Low-WAC strategic pricing, while Vegzelma expects 2H sales growth following two major PBM listings(July 2026)

Yuflyma Global M/S



* Market share based on prescription volume
* Source: IQVIA, Farminform, Symphony Health

Vegzelma Global M/S




* Market share based on prescription volume
* Source: IQVIA, Farminform, Symphony Health

Performance of 5 Newly Launched Products



- Robust top-line expansion across all new products, surpassing KRW 300 billion in combined sales (+49% QoQ)
- Explosive sales growth driven by outstanding performance of Omlyclo(first-mover advantage in an uncontested market) and Avtozma(consecutive European public tender wins & on-track US PBM listings)
- Additional growth momentum in 2H through US launches of Omlyclo and Eydenzelt

Global Sales of Five New Products



Major Market Launch & Early Commercial Results

 ustekinumab	Europe '24.11	Growth accelerating via AI formulation rollout & upcoming UC indication expansion
	US '25.03	Achieved 12% M/S within one year of launch (2Q26), driven by a top-3 PBM listing, full-label approval, and synergy with a broad autoimmune portfolio
 omalizumab	Europe '25.09	Exclusive market dominance as a first-mover with no competitors; reaching 21% M/S within three quarters (1Q26)
	US 2H26(e)	Scheduled for US launch as a first-mover with no competitors; expecting to replicate strong EU performance
 denosumab &  denosumab	Europe '25.12	Driving M/S expansion by leveraging portfolio synergy and 9,000-pharmacy network of Gifrer, acquired in May 2026
	US '25.07	Preferred drug listings secured across 3 of top 5 PBMs, establishing an early stronghold amid competitive landscape
 tocilizumab	Europe '26.01	Rapidly expanding sales upon launch after winning public tenders in multiple EU5 countries
	US '25.10	Prescription growth expected via commercial listings with top 3 PBMs and public + commercial coverage via Prime Therapeutics (#5 PBM)
 afilibercept	Europe '26.01	Secured UK NHS tender immediately upon launch; market share expected to expand as supply stabilizes in 2H
	US 2H26(e)	Preparations on track for 2H launch


03

Development & Production Strategy

Biosimilar Market Landscape

- Growth concentrated on top-tier companies with integrated R&D, manufacturing, and sales capabilities, sustaining industry consolidation
- Celltrion strengthening market dominance leveraging the highest revenue growth rate and fastest portfolio expansion among Top 3

Portfolio & Revenue Comparison of Major Global Biosimilar Companies³



1. Annual biosimilar revenue based on IQVIA Analytics

2. Number of biosimilar portfolio products, excluding insulins

3. Manufacturers with biosimilars of identical molecules launched by Celltrion in US and EU markets in 2023 and 2025

4. Global Top 3 refers to companies with annual biosimilar revenue over \$2bn in 2023 and over \$4bn in 2025

Biosimilar R&D Update & Mid/Long-Term Strategy

- Phase 1 clinical trials initiated for Entyvio® and Tremfya® biosimilars; regulatory filings completed for Cosentyx® (Europe) biosimilar
- R&D progress on track for 7 biosimilars projects; strengthening global biosimilar leadership via 18-product portfolio by 2030 and 41 by 2038


R&D Progress

Indication	Product Name	Global Market Size (2025)	Development Status	
			US	EU
Autoimmune Diseases	CT-P53 (OCREVUS® Biosimilar)	\$9.0bn	In Phase 3 Clinical Trial	
	CT-P55 (COSENTYX® Biosimilar)	\$11.2bn	Regulatory filing planned	Regulatory filing submitted
	CT-P52 (TALTZ® Biosimilar)	\$7.0bn	In Phase 1 Clinical Trial	
	CT-P45 (ENTYVIO® Biosimilar)	\$7.3bn	In Phase 1 Clinical Trial	
	CT-P68 (TREMFYA® Biosimilar)	\$10.5bn	In Phase 1 Clinical Trial (IND ¹ Approved by MFDS)	
Oncology	CT-P6 SC (HERCEPTIN SC® Biosimilar)	\$1.2bn ²	-	Regulatory filing submitted
NSCLC ³	CT-P51 (KEYTRUDA® Biosimilar)	\$36.5bn	In Phase 3 Clinical Trial	
Multiple Myeloma	CT-P44 (DARZALEX® Biosimilar)	\$14.4bn	In Phase 3 Clinical Trial	


Portfolio Status

----- Pre-approval



 Immunology



Oncology



Other Therapeutic Areas

 Undisclosed Pipelines

1. IND (Investigational New Drug Application): A regulatory submission to obtain approval from relevant authorities to commence clinical trials in humans

2. Based on the Trastuzumab market in Europe (2025)

3. NSCLC: Non-Small Cell Lung Cancer

* Source: IQVIA, J&J(DARZALEX)

Novel Drug R&D Status

- Phase 1 clinical trials for 3 ADC pipelines progressing smoothly; top-line data release for 2 candidates expected early next year
- Multispecific antibody pipeline(CT-P72) entered Phase 1, confirming robust pre-clinical anticancer efficacy & tolerability in high-dose

CT-P70_cMET

NSCLC¹ / CRC² / Gastric cancer

FDA Fast Track
Designated

Phase 1 Ongoing

CT-P71_Nectin-4

UC³ / Breast cancer / Prostate cancer

FDA Fast Track
Designated

Phase 1 Ongoing

CT-P73_CD142

Cervical cancer / H&N⁴ / CRC

FDA Fast Track
Filed

Phase 1 Ongoing

CT-P72_HER2 x CD3

Breast cancer / Gastric cancer/
CRC / Endometrial cancer

FDA Fast Track
Filing Planned

Phase 1 Ongoing

ADC Pipelines Phase 1 on Track

- ✓ **Validated targets/antibodies minimize risks**, with upside for efficacy gains and indication expansion
- ✓ 2 pipelines FDA Fast Track designated—**maximizing development efficiency**
- ✓ **Superior tolerability** vs. competitors with same Topo1i payload, supporting potential for higher dosing

MsAb Pipeline in Phase 1

- ✓ Presented preclinical data at the World Bispecific & T-Cell Engager Summit South Korea(26.06)
- ✓ High-dose tolerability confirmed in MPS⁵ model—securing rationale for Phase 1 clinical entry

1. NSCLC: Non-Small Cell Lung Cancer; 2. CRC: Colorectal Cancer; 3. UC: Urothelial Carcinoma; 4. H&N: Head and Neck Cancer
5. MPS: Microphysiological Systems



04

Appendix

Earnings Summary Consolidated



Quarterly

	2Q25	3Q25	4Q25	1Q26	2Q26
Sales	962	1,029	1,330	1,145	1,394
Cost of Sales	417	403	477	459	530
Gross Profit	544	626	854	686	864
GP Margin	56.6%	60.8%	64.2%	59.9%	62.0%
SG&A	302	325	379	364	412
- R&D Expenses	46	55	53	62	64
Operating Profit	243	301	475	322	452
OP Margin	25.2%	29.3%	35.7%	28.1%	32.4%
Profit before Income Tax	52	378	528	432	458
Net Profit	63	332	528	350	371
NP Margin	6.6%	32.3%	39.7%	30.6%	26.6%

6-Month Cumulative

[Unit: KRW billion]

	2025	2026	YoY
	1,803	2,539	+40.8%
	816	989	+21.1%
	987	1,550	+57.0%
	54.7%	61.1%	+6.4%p
	595	776	+30.4%
	103	126	+22.6%
	392	774	+97.4%
	21.7%	30.5%	+8.8%p
	248	890	+259.0%
	172	721	+320.2%
	9.5%	28.4%	+18.9%p

* Figures are rounded to the nearest KRW 1 billion; minor discrepancies may occur due to rounding

Sales Mix by Product



Quarterly

	2Q25	3Q25	4Q25	1Q26	2Q26
Sales	962	1,029	1,330	1,145	1,394
Biologics	883	961	1,252	974	1,264
Advanced Products	415	440	518	393	439
Remsima IV	261	265	285	214	253
Truxima	103	126	169	137	152
Herzuma	51	49	64	43	34
Young Products	468	521	735	581	825
Remsima SC	161	185	236	157	200
Yuflyma	137	144	104	114	195
Vegzelma	80	75	155	46	69
Zymfentra	23	28	58	53	47
Steqeyma	35	35	42	40	50
Omlyclo	22	28	49	72	117
Eydenzelt	2	2	6	7	10
Stoboclo/Osenvelt	7	20	71	69	74
Avtozma	1	4	14	25	64
Non-Biologics	79	68	78	171	130
CT Pharm/Chemical	72	63	70	69	73
CMO	-	-	-	96	50
Others	7	5	8	5	7

6-Month Cumulative

[Unit: KRW billion]

	2025	2026	YoY
Sales	1,803	2,539	+40.8%
Biologics	1,650	2,238	+35.6%
Advanced Products	835	832	-0.4%
Remsima IV	499	467	-6.4%
Truxima	231	289	+24.8%
Herzuma	105	76	-27.3%
Young Products	815	1,406	+72.5%
Remsima SC	296	357	+20.3%
Yuflyma	255	310	+21.4%
Vegzelma	139	115	-17.5%
Zymfentra	36	100	+176.4%
Steqeyma	57	90	+58.9%
Omlyclo	22	188	+756.4%
Eydenzelt	2	17	+894.1%
Stoboclo/Osenvelt	8	142	+1,720.5%
Avtozma	1	89	+9,744.4%
Non-Biologics	153	301	+96.5%
CT Pharm/Chemical	140	142	+1.4%
CMO	0	147	-
Others	13	12	-9.4%

* Figures are rounded to the nearest KRW 1billion; minor discrepancies may occur due to rounding

Advanced Therapeutics within Everyone's Reach

Thank you